Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis
Recruiting now · Not applicable
Conditions studied: Pancreatic Cancer
In brief
1. Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. 2. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. 3. Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.
Key facts
- Study ID
- NCT06307080
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
- People needed
- 12
- Starts
- 2023-10-08
- Expected to finish
- 2026-12-31
- Last updated by the study team
- 2025-07-09
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- age 18-70 years old, gender is not limited;
- Newly diagnosed pancreatic cancer with liver metastasis confirmed by pathology or consistent with clinical diagnosis, and no metastases to organs other than the liver;
- Imaging evaluable tumors with safe access to puncture;
- The number of half liver tumors ≤3 and the size of each tumor ≤3 cm;
- ECOG PS score ≤2 points, expected survival > 3 months.
You may not qualify if…
- Liver function Child-Pugh grade C, severe jaundice, especially obstructive jaundice;
- The liver is significantly atrophy, the tumor is too large, and the ablation range needs to reach one-third of the liver volume;
- Expected survival < 3 months;
- serious heart, lung, liver and kidney dysfunction and coagulation dysfunction;
- Uncontrolled co-morbidities, including poorly controlled hypertension or diabetes, persistent active infections, or mental illness or social conditions that may affect participants' compliance with the study;
- refractory ascites, pleural fluid or bad fluid;
- Pregnancy or breastfeeding;
- The researcher considers that there are any other factors that are not suitable for inclusion or affect the participant's participation in the study.
Where it is running
- Shanghai General Hospital — Shanghai, Shanghai Municipality, China (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.